Christopher L. Murriel PhD

Christopher L. Murriel received his B.A. from Washington University in St. Louis, MO, where he majored in Chemistry with a concentration in biochemistry. He next received his Ph.D. from Daria Mochly-Rosen’s lab in the Department of Molecular Pharmacology at Stanford University School of Medicine where he studied the effects of protein kinase C in rodent models of cardiac ischemia and reperfusion damage. Before joining OncoMed Pharmaceuticals, he completed his Postdoctoral Fellowship in the Department of Molecular Biology with David Davis and Leisa Johnson at Genentech.

His work at Genentech focused on identifying synthetic lethal interacting partners with mutant KRAS, utilizing high-throughput RNAi screening platforms. In addition, he helped develop genetically engineered mouse models of conditional non-small cell lung carcinoma and pancreatic ductal adenocarcinoma for pre-clinical in vivo drug testing.